Medtronic has maintained a 49-year streak of raising dividends, despite its stock losing 20% over five years. Recently, the company reported faster growth driven by its cardiac ablation business, which grew 88% globally and 139% in the U.S., signaling a shift from dividend income to growth potential. With a dividend yield of about 3.27% and solid cash flow coverage, the dividend remains a floor for investors, while innovations in ablation and other areas offer upside. The upcoming investor day in December will provide further insights on growth prospects and margin improvements.
Medtronic's stock price at USD 86.38 is closer to its 52-week low of USD 73.75 than its high of USD 105.35 as of Oct 03, 2026 18:31 WIB, showing some distance from its peak despite steady dividend increases. Its dividend yield of 3.33% on Pluang slightly exceeds the article's 3.27% figure, reflecting a consistent income stream amid a mostly selling sentiment with 97% of orders being sell. The typical hold time of 63 days suggests moderate investor engagement with the stock during this period.
The American Medical Association (AMA) has approved new Category I CPT codes for Medtronic's Altaviva™ implantable tibial neuromodulation device and Symplicity Spyral™ renal denervation system. These devices treat urge urinary incontinence and uncont...
Medtronic announced FDA clearance and CE Mark for its latest Affera Prism-2 Mapping Software and CE Mark for the PulseSelect ProxBox Adapter with Proximity Indicator software. These upgrades enhance cardiac ablation procedures by providing detailed 3...
Abbott Laboratories, Medtronic, and Becton Dickinson, three leading medical device companies, have each increased their dividends recently, continuing long streaks of annual raises—54 years for Abbott, 49 for Medtronic, and consistent growth for Bect...
